^
Association details:
| Biomarker: | FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | JRF104 (FLT3 inhibitor, AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3766 / 20 - Development of new FLT3/AXL dual inhibitor JRF104 with potent FLT3-TKD inhibition
Published date:
05/27/2020
Excerpt:
In vitro studies suggested that JRF104 could potently inhibit the proliferation of MV4-11 and Molm-13 cells, which endogenously express FLT3-ITD mutation…In Molm-13 xenograft model, tumor volume was well controlled at 15 mg/kg, QD (TGI: 94%), and all tumor volume reduced to zero at 50 mg/kg, QD (TGI: 104%).
Source:
Title:
3766 / 20 - Development of new FLT3/AXL dual inhibitor JRF104 with potent FLT3-TKD inhibition
Published date:
05/27/2020
Excerpt:
In CT-26 syngeneic model, JRF104 enhanced anti-tumor growth effect when combined with anti-PD-1 antibody and suppressed pERK and pAKT in tumor tissues.
Secondary therapy:
Undisclosed PD-1 inhibitor
